Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.50 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | CALML3 | P27482 | 1/20 | 0.50 |
| ▸ | SDHA | P31040 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6040521 | 0.91 | MAOA (0.50) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6040235 | 0.89 | MAOA (0.53) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6040230 | 0.89 | MAOA (0.53) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6040232 | 0.88 | MAOA (0.54) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6594893 | 0.87 | MAOA (0.51) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6040582 | 0.86 | MAOA (0.51) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6040423 | 0.85 | MAOA (0.49) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6594883 | 0.84 | MAOA (0.52) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6040425 | 0.84 | MAOA (0.49) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6040331 | 0.82 | MAOA (0.51) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237889-B1 | ANTIBIOTIC SULTAM AND SULTONE DERIVED OXAZOLIDINONES | UPJOHN CO (US) | 2004-09-01 | — | — | EP | claimed |
| US-20020055505-A1 | SULTAM AND SULTONE DERIVED OXAZOLIDINONES | ANDERSON DAVID JOHN (US) | 2002-05-09 | — | — | US | claimed |
| US-6348459-B1 | DRUGS AND ANTIBIOTIC AGENTS. | PHARMACIA AND UPJOHN COMPANY | 2002-02-19 | — | — | US | claimed |
| US-7049443-B2 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | PHARMACIA & UPJOHN COMPANY (US) | 2006-05-23 | — | — | US | disclosed |
| EP-1237889-B1 | ANTIBIOTIC SULTAM AND SULTONE DERIVED OXAZOLIDINONES | UPJOHN CO (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040014967-A1 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | PHARMACIA & UPJOHN COMPANY | 2004-01-22 | — | — | US | disclosed |
| US-6420360-B1 | ANTIBIOTIC AGENTS. | PHARMACIA & UPJOHN COMPANY | 2002-07-16 | — | — | US | disclosed |
| US-20020055505-A1 | SULTAM AND SULTONE DERIVED OXAZOLIDINONES | ANDERSON DAVID JOHN (US) | 2002-05-09 | — | — | US | disclosed |
| US-6348459-B1 | DRUGS AND ANTIBIOTIC AGENTS. | PHARMACIA AND UPJOHN COMPANY | 2002-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055505-A1 | SULTAM AND SULTONE DERIVED OXAZOLIDINONES | SULT1A1, SULT1E1, SULT2A1 | MAOA 1669/4885MAOB 2010/4885LMNA 4746/4885 |
| US-20040014967-A1 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | AADAC, AAAS, SLC7A1 | MAOA 1179/4885MAOB 732/4885LMNA 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.